普拉克索增效治疗单相和双相抑郁症：一项回顾性病历审查
Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review.
作者信息
Sporn J, Ghaemi S N, Sambur M R, Rankin M A, Recht J, Sachs G S, Rosenbaum J F, Fava M
机构信息
Department of Psychiatry, Massachusetts General Hospital, USA.
出版信息
Ann Clin Psychiatry. 2000 Sep;12(3):137-40. doi: 10.1023/a:1009060800999.
OBJECTIVE
To assess the effectiveness and safety of pramipexole as an adjunctive medication in refractory bipolar and unipolar depression in a naturalistic setting.
METHODS
Retrospective chart review by psychiatrists on staff at a university hospital identified all patients who had received pramipexole. Response was based on moderate to marked improvement in the Clinical Global Impression-Improvement (CGI-I) scale.
RESULTS
Pramipexole (mean dose 0.70 mg/d, mean duration 24.4 weeks) was effective in 6/12 (50.0%) of patients with bipolar depression, and 8/20 (40%) of patients with unipolar depression, mean duration of follow-up of 24.4 weeks. One case of transient hypomania was noted. Eight patients discontinued pramipexole due to lack of response and four due to side effects.
CONCLUSIONS
Pramipexole, used as an adjunct to antidepressants or mood stabilizers, appeared to be effective and safe in the treatment of unipolar and bipolar depression. These uncontrolled, retrospective, naturalistic pilot data require confirmation by controlled research before conclusions can be made.
目的
在自然环境中评估普拉克索作为难治性双相和单相抑郁症辅助药物的有效性和安全性。
方法
大学医院的精神科医生对工作人员的病历进行回顾性审查，确定所有接受过普拉克索治疗的患者。疗效基于临床总体印象改善量表（CGI-I）中达到中度至显著改善。
结果
普拉克索（平均剂量0.70毫克/天，平均疗程24.4周）对6/12例（50.0%）双相抑郁症患者和8/20例（40%）单相抑郁症患者有效，平均随访时间为24.4周。记录到1例短暂性轻躁狂病例。8例患者因无反应而停用普拉克索，4例因副作用停药。
结论
普拉克索作为抗抑郁药或心境稳定剂的辅助药物，在治疗单相和双相抑郁症时似乎有效且安全。在得出结论之前，这些非对照、回顾性、自然环境下的初步数据需要通过对照研究加以证实。
Zotero 插件